Intro

This chapter explores the FDA's unexpected decision to deny approval for MDMA-assisted therapy for PTSD, despite strong evidence supporting its effectiveness. It reflects on the 40-year journey of this treatment, highlighting past challenges and the potential implications for the future of psychedelic therapies.